Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE11.8500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots10.0000/ 2
- Ask / Lots16.5700/ 2
- Open / Previous Close0.0000 / 11.8500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 872 | 12.21 |
| 09:41 ET | 100 | 12.19 |
| 09:43 ET | 585 | 12.13 |
| 09:45 ET | 530 | 12.135 |
| 09:48 ET | 100 | 12.125 |
| 09:52 ET | 100 | 12.11 |
| 09:54 ET | 1270 | 11.94 |
| 10:01 ET | 1100 | 12.115 |
| 10:03 ET | 100 | 12.12 |
| 10:10 ET | 3741 | 12.095 |
| 10:12 ET | 3242 | 12.115 |
| 10:14 ET | 2201 | 12.17 |
| 10:17 ET | 100 | 12.12 |
| 10:19 ET | 100 | 12.13 |
| 10:24 ET | 100 | 12.11 |
| 10:30 ET | 426 | 12.07 |
| 10:32 ET | 842 | 12.109 |
| 10:33 ET | 200 | 12.105 |
| 10:37 ET | 1000 | 12.1017 |
| 10:39 ET | 398 | 12.15 |
| 10:44 ET | 100 | 12.13 |
| 10:46 ET | 1326 | 12.15 |
| 10:48 ET | 100 | 12.24 |
| 10:50 ET | 300 | 12.18 |
| 10:57 ET | 100 | 12.165 |
| 11:02 ET | 1933 | 12.24 |
| 11:06 ET | 100 | 12.3 |
| 11:09 ET | 100 | 12.31 |
| 11:11 ET | 770 | 12.225 |
| 11:15 ET | 1669 | 12.2 |
| 11:18 ET | 200 | 12.18 |
| 11:20 ET | 486 | 12.21 |
| 11:26 ET | 592 | 12.25 |
| 11:27 ET | 1218 | 12.29 |
| 11:29 ET | 956 | 12.36 |
| 11:31 ET | 200 | 12.39 |
| 11:33 ET | 300 | 12.36 |
| 11:38 ET | 1915 | 12.24 |
| 11:42 ET | 1037 | 12.1992 |
| 11:54 ET | 300 | 12.17 |
| 11:56 ET | 400 | 12.13 |
| 12:00 ET | 647 | 12.13 |
| 12:02 ET | 200 | 12.09 |
| 12:14 ET | 787 | 12.1 |
| 12:18 ET | 1275 | 12.06 |
| 12:25 ET | 100 | 12.05 |
| 12:27 ET | 100 | 12.04 |
| 12:30 ET | 798 | 12.1 |
| 12:32 ET | 600 | 12.07 |
| 12:36 ET | 216 | 12.06 |
| 12:39 ET | 817 | 12.08 |
| 12:41 ET | 100 | 12.08 |
| 12:45 ET | 475 | 12.0761 |
| 12:50 ET | 200 | 12.075 |
| 12:54 ET | 450 | 12.08 |
| 12:56 ET | 458 | 12.085 |
| 12:57 ET | 763 | 12.04 |
| 01:06 ET | 500 | 11.98 |
| 01:08 ET | 200 | 12 |
| 01:12 ET | 250 | 11.9954 |
| 01:17 ET | 100 | 12.04 |
| 01:19 ET | 200 | 12.03 |
| 01:21 ET | 1740 | 12 |
| 01:28 ET | 100 | 11.995 |
| 01:30 ET | 800 | 12.02 |
| 01:33 ET | 100 | 12.02 |
| 01:37 ET | 100 | 11.99 |
| 01:39 ET | 700 | 11.97 |
| 01:42 ET | 431 | 11.98 |
| 01:44 ET | 200 | 11.98 |
| 01:46 ET | 398 | 11.99 |
| 01:50 ET | 100 | 11.995 |
| 01:51 ET | 100 | 12.02 |
| 01:55 ET | 700 | 11.98 |
| 01:57 ET | 350 | 11.974 |
| 02:00 ET | 442 | 11.98 |
| 02:06 ET | 700 | 11.96 |
| 02:08 ET | 600 | 11.93 |
| 02:11 ET | 502 | 11.9 |
| 02:24 ET | 600 | 11.87 |
| 02:26 ET | 633 | 11.9 |
| 02:27 ET | 100 | 11.93 |
| 02:31 ET | 100 | 11.95 |
| 02:33 ET | 100 | 11.95 |
| 02:36 ET | 500 | 11.91 |
| 02:42 ET | 600 | 11.935 |
| 02:45 ET | 100 | 11.95 |
| 02:47 ET | 2326 | 11.93 |
| 02:49 ET | 361 | 11.93 |
| 02:51 ET | 320 | 11.93 |
| 03:00 ET | 770 | 11.96 |
| 03:02 ET | 100 | 11.98 |
| 03:03 ET | 1255 | 11.92 |
| 03:05 ET | 600 | 11.87 |
| 03:09 ET | 274 | 11.86 |
| 03:14 ET | 1148 | 11.88 |
| 03:16 ET | 100 | 11.88 |
| 03:21 ET | 100 | 11.88 |
| 03:23 ET | 235 | 11.9 |
| 03:25 ET | 200 | 11.93 |
| 03:27 ET | 1435 | 11.9 |
| 03:30 ET | 447 | 11.9 |
| 03:32 ET | 729 | 11.9 |
| 03:34 ET | 1300 | 11.88 |
| 03:36 ET | 1051 | 11.88 |
| 03:38 ET | 428 | 11.88 |
| 03:39 ET | 809 | 11.84 |
| 03:41 ET | 992 | 11.855 |
| 03:43 ET | 1213 | 11.87 |
| 03:45 ET | 892 | 11.84 |
| 03:48 ET | 793 | 11.82 |
| 03:50 ET | 3919 | 11.78 |
| 03:52 ET | 507 | 11.78 |
| 03:54 ET | 1129 | 11.81 |
| 03:56 ET | 3206 | 11.78 |
| 03:57 ET | 4297 | 11.77 |
| 03:59 ET | 10426 | 11.85 |
May 13, 2024
DJ Y-mAbs Therapeutics Price Target Raised to $22.00/Share From $21.00 by HC Wainwright & Co., from 1:51PM ET on Monday May 13, 2024 by Dow Jones
1:51PM ET on Monday May 13, 2024 by Dow Jones
May 8, 2024
DJ Y-mAbs Therapeutics Down Over 17%, on Pace for Largest Percent Decrease Since October 2022 -- Data Talk, from 1:15PM ET on Wednesday May 08, 2024 by Dow Jones
1:15PM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones*DJ Y-mAbs Therapeutics 1Q Loss/Shr 15c >YMAB, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
Apr 26, 2024
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024, from 7:05AM ET on Friday Apr 26, 2024 by Dow Jones
7:05AM ET on Friday Apr 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 520.0M | -23.9x | --- |
Urogen Pharma Ltd | 477.3M | -3.9x | --- |
Editas Medicine Inc | 484.4M | -2.8x | --- |
Alector Inc | 529.2M | -4.0x | --- |
Fate Therapeutics Inc | 471.3M | -2.2x | --- |
Zymeworks Inc | 663.2M | -5.3x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Bo Kruse
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $520.0M |
|---|---|
Revenue (TTM) | $84.5M |
Shares Outstanding | 43.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-0.50 |
Book Value | $2.31 |
P/E Ratio | -23.9x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
